At close: June 28 at 4:00 PM EDT
After hours: June 28 at 5:42 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 11 | 12 |
| Avg. Estimate | -0.4 | -0.41 | -1.68 | -1.54 |
| Low Estimate | -0.43 | -0.45 | -1.82 | -1.8 |
| High Estimate | -0.37 | -0.34 | -1.46 | -1.13 |
| Year Ago EPS | -0.47 | -0.55 | -2.18 | -1.68 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 9 | 12 | 10 |
| Avg. Estimate | 1.63M | 370k | 4.81M | 4.38M |
| Low Estimate | -- | -- | 590k | -- |
| High Estimate | 13M | 2M | 40M | 35.8M |
| Year Ago Sales | -- | -- | -- | 4.81M |
| Sales Growth (year/est) | -- | -- | -- | -8.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.42 | -0.46 | -0.51 | -0.47 |
| EPS Actual | -0.47 | -0.55 | -0.72 | -0.44 |
| Difference | -0.05 | -0.09 | -0.21 | 0.03 |
| Surprise % | -11.90% | -19.60% | -41.20% | 6.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.41 | -1.68 | -1.54 |
| 7 Days Ago | -0.4 | -0.41 | -1.68 | -1.54 |
| 30 Days Ago | -0.4 | -0.41 | -1.68 | -1.54 |
| 60 Days Ago | -0.44 | -0.45 | -1.83 | -1.64 |
| 90 Days Ago | -0.44 | -0.45 | -1.85 | -1.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRME | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 14.90% | -- | -- | 6.80% |
| Next Qtr. | 25.50% | -- | -- | 10.20% |
| Current Year | 22.90% | -- | -- | 4.10% |
| Next Year | 8.30% | -- | -- | 12.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.36% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | HC Wainwright & Co.: Buy | 5/20/2024 |
| Upgrade | Citigroup: Neutral to Buy | 5/16/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 5/13/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 4/23/2024 |
| Initiated | Chardan Capital: Buy | 4/22/2024 |
| Initiated | TD Cowen: Buy | 4/8/2024 |
Related Tickers
ABSI Absci Corporation
3.0800
+0.98%
BEAM Beam Therapeutics Inc.
23.43
-2.29%
VERV Verve Therapeutics, Inc.
4.8800
+2.52%
BCYC Bicycle Therapeutics plc
20.24
-0.15%
CRBU Caribou Biosciences, Inc.
1.6400
-2.38%
NTLA Intellia Therapeutics, Inc.
22.38
-3.49%
ARQT Arcutis Biotherapeutics, Inc.
9.30
-1.27%
SANA Sana Biotechnology, Inc.
5.46
+1.11%
MGX Metagenomi, Inc.
4.0800
+8.22%
EDIT Editas Medicine, Inc.
4.6700
-1.48%